Most of the companies with blockbuster drugs approved over the past decade oversaw their clinical development internally. Lilly holds the lead with eight blockbusters developed in-house.

As South Korea's doctors continue their long-running protest against a government plan to raise the medical student quota at universities, the walk-outs may be beginning to take a toll on the pharma industry, with many large firms reporting weak earnings in the last quarter.

Korean bioventures join an inaugural matching event with Japanese pharma firms at Shonan iPark, amid rising hopes for further bilateral partnerships based on respective R&D capabilities.

Herbal and nutritional supplement direct seller has reached 85% solar power use at its US facilities while also reducing landfill waste from those sites more than 90%, cutting its US shipping routes by half and consolidating four distribution centers in Europe into one operating on wind power.